 AIM ImmunoTech Inc NYSE:AIM. has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer AMP-270, with clinical trial on track to start in the third quarter of this year. 